福多司坦片联合阿米卡星治疗医院获得性肺炎的效果及对血清皮质醇、肺表面活性蛋白D水平的影响研究

福多司坦片联合阿米卡星治疗医院获得性肺炎的效果及对血清皮质醇、肺表面活性蛋白D水平的影响研究

亓梅,冯倩,李珍,张鹏,韩其政

山东省立医院西院,山东省立医院西院,山东省立医院西院,山东省立医院西院,山东省立医院西院

收稿日期:2018-07-11 修回日期:2018-07-17 出版日期:2018-06-25
基金资助:
济南市科技计划项目（项目编号：201302164；项目名称：慢性阻塞性肺疾病三级防控网络的构建）

Effects of Fudosteine and Amikacin on Hospital Acquired Pneumonia and its Effect on Serum Cortisol and Pulmonary Surfactantprotein D Levels

Qi Mei,Feng Qian,Li zhen,Zhang Peng and Han Qizheng

Shandong Provincial Hospital West Hospital,Shandong Provincial Hospital West Hospital,Shandong Provincial Hospital West Hospital,Shandong Provincial Hospital West Hospital,Shandong Provincial Hospital West Hospital

Received:2018-07-11 Revised:2018-07-17 Online:2018-06-25

摘要/Abstract

摘要： 目的：探究福多司坦片联合阿米卡星治疗医院获得性肺炎(HAP)的效果及对血清皮质醇（COR）、肺表面活性蛋白D（SP-D）水平的影响。方法：选取2017年2月至2018年2月在我院住院治疗后发生HAP的患者90例作为研究对象，按照随机数字表法分为对照组和观察组，每组各45例。对照组给予阿米卡星治疗，观察组给予福多司坦片联合阿米卡星治疗。比较两组患者治疗的临床疗效和不良反应，检测并比较两组患者治疗前后的肿瘤坏死因子-α（TNF-α）、白细胞介素-6（IL-6）和血清COR、SP-D水平。结果：观察组的有效率高于对照组，差异有统计学意义（P＜0.05）。治疗后两组的血清炎症因子均降低，治疗后观察组的血清TNF-α、IL-6均低于对照组，差异有统计学意义（P＜0.05）。治疗后两组COR、SP-D均降低，治疗后观察组的血清COR、SP-D均低于对照组，差异有统计学意义（P＜0.05）。两组不良反应总发生率差异无统计学意义（P＞0.05）。结论：福多司坦片联合阿米卡星对HAP具有更好的临床疗效，并且可有效降低机体的炎性水平，降低血清COR、SP-D水平，提高预后。

Abstract: Objective：To investigate the effects of fudosteine and amikacin on hospital acquired pneumonia (HAP) and its effect on serum cortisol（COR） and pulmonary surfactantprotein D（SP-D） levels.Methods： A total of 90 patients with HAP after hospitalization in our hospital from February 2017 to February 2018 were selected and divided into the control group(n=45) and the observation group(n=45) according to a digital randomized table method. The control group was treated with amikacin and the observation group was treated with fudostine on the basis of the control group.The clinical efficacy and adverse reactions of the two groups of patients were compared. The levels of inflammatory factors and serum COR and SP-D levels before and after treatment were detected and compared between the two groups. Results： The effective rate of the observation group was higher than that of the control group， the difference was statistically significant(P＜0.05). Serum inflammatory factors were decreased in both groups after treatment. Serum TNF-α and IL-6 levels in the observation group were lower than those in the control group， the difference was statistically significant(P＜0.05). After treatment， serum COR and SP-D were decreased in the two groups. Serum COR and SP-D in the observation group were lower than those in the control group，the difference was statistically significant(P＜0.05).There was no statistically significant(P＜0.05) in the overall incidence of adverse events between the two groups (P＞0.05). Conclusion： Fudosteine combined with amikacin has better clinical efficacy on HAP， and can effectively reduce the body′s inflammatory levels， reduce serum COR， SP-D levels and improve the prognosis.

亓梅,冯倩,李珍,张鹏,韩其政. 福多司坦片联合阿米卡星治疗医院获得性肺炎的效果及对血清皮质醇、肺表面活性蛋白D水平的影响研究[J]. .

Qi Mei,Feng Qian,Li zhen,Zhang Peng and Han Qizheng. Effects of Fudosteine and Amikacin on Hospital Acquired Pneumonia and its Effect on Serum Cortisol and Pulmonary Surfactantprotein D Levels[J]. .

参考文献

[1] Sopena N, Heras E, Casas I, et al. Risk factors for hospital-acquired pneumonia outside the intensive care unit: A case-control study[J]. Ajic American Journal of Infection Control, 2014, 42(1):38-42.
[2] 焦洋, 黄怡. 《2014 NICE临床指南:成人社区和医院获得性肺炎诊断和管理》解读[J]. 中国实用内科杂志, 2015, 35(5):411-413.
[3] 杨青茹, 李若然. 福多司坦联合布地奈德治疗慢性阻塞性肺疾病急性加重期的临床研究[J]. 现代药物与临床, 2017, 32(12):2368-2372.
[4] Mavroudis P D, Corbett S A, Calvano S E, et al. Circadian characteristics of permissive and suppressive effects of cortisol and their role in homeostasis and the acute inflammatory response[J]. Mathematical Biosciences, 2015, 2(260):54-56.
[5] Güzel A, Karada? A, Okuyucu A, et al. The evaluation of serum surfactant protein D (SP-D) levels as a biomarker of lung injury in tuberculosis and different lung diseases[J]. Clinical Laboratory, 2014, 60(7):1091-1098.
[6] 中华医学会呼吸病学分会感染学组. 中国成人医院获得性肺炎与呼吸机相关性肺炎诊断和治疗指南(2018年版)[J]. 中华结核和呼吸杂志, 2018, 41(4): 255-280.
[7] 李莲花, 杨倩, 栾禹博,等. T细胞亚群与临床肺部感染评分在老年院内获得性肺炎预后评价中的作用[J]. 中华急诊医学杂志, 2014, 23(4):377-381.
[8] Asehnoune K, Seguin P, Allary J, et al. Hydrocortisone and fludrocortisone for prevention of hospital-acquired pneumonia in patients with severe traumatic brain injury (Corti-TC): a double-blind, multicentre phase 3, randomised placebo-controlled trial.[J]. Lancet Respiratory Medicine, 2014, 2(9):706-716.
[9] 聂晓莉, 闫春良, 赵秋红,等. 医院内获得性肺炎抗菌药物的疗效和安全性比较[J]. 中国医院药学杂志, 2015, 35(13):1225-1227.
[10] 闻海丰, 赵建宏, 时东彦,等. 河北省细菌耐药监测网耐药数据质量分析:鲍曼不动杆菌对阿米卡星耐药数据问题初步探讨[J]. 中国抗生素杂志, 2016, 41(7):557-560.
[11] 杨玉华, 曹秀萍, 吴庆勇,等. 糖尿病并发获得性肺部感染患者病原菌分布及药物敏感性研究[J]. 中华医院感染学杂志, 2017, 27(18):4143-4146.
[12] 高云阁, 翟树森, 崔庆超,等. 老年肿瘤患者嗜麦芽窄食单胞菌致院内获得性肺炎的临床特点及其危险因素[J]. 武警医学, 2016, 27(2):154-157.
[13] 谢诤, 江莲, 谢伟国,等. 福多司坦片在慢性呼吸系统疾病中的祛痰效果[J]. 江苏医药, 2014, 40(23):2890-2891.
[14] 袁琪, 林勇. 福多司坦对慢性阻塞性肺病急性加重期患者预后的影响[J]. 临床肺科杂志, 2016, 21(10):1802-1804.
[15] 唐华强. 用振动排痰法与福多司坦治疗老年性肺炎的效果分析[J]. 当代医药论丛, 2016, 14(16):69-70.
[16] 魏华生, 吴波, 胡筱,等. 福多司坦对慢性阻塞性肺疾病急性加重期患者痰液黏蛋白5AC研究[J]. 中国实用内科杂志, 2017, 37(8): 751-753.
[17] 杨青茹, 李若然. 福多司坦联合布地奈德治疗慢性阻塞性肺疾病急性加重期的临床研究[J]. 现代药物与临床, 2017, 32(12):2368-2372.
[18] Du Y J, Yang C J, Li B, et al. Association of pro-inflammatory cytokines, cortisol and depression in patients with chronic obstructive pulmonary disease[J]. Psychoneuroendocrinology, 2014, 46(4):141-152.
[19] 黄莹, 谭超超. 内皮素受体阻断对重症急性胰腺炎病情及炎症反应的影响[J]. 广东医学, 201536, (9):1327-1331.
[20] 周晓莉, 饶一武, ZHOUXiao-li,等. 应激状态下患者下丘脑-垂体-肾上腺轴功能的变化[J]. 医学综述, 2014, 20(13):2439-2440.
[21] 麦玉梅, 李伟峰, 黄文杰. 重症肺炎患者血清皮质醇的动态变化及临床意义[J]. 临床肺科杂志, 2016, 1(3):437-439.
[22] Thacker S, Moran A, Lionakis M, et al. Restoration of lung surfactant protein D by IL-6 protects against secondary pneumonia following hemorrhagic shock.[J]. Journal of Infection, 2014, 68(3):231-241.
[23] 王鹂鹂, 郑首燕, 任洛,等. 肺炎患儿支气管肺泡灌洗液中肺表面活性蛋白A和D表达及其与肺炎临床特征的相关性[J]. 中国当代儿科杂志, 2016, 18(5):386-390.
[24] 周淑芳, 姜秀峰, 卞涛,等. 福多司坦对重度阻塞性睡眠呼吸暂停综合征患者Th1、Th2细胞以及血清中IFN-γ和IL-4的影响[J]. 中华老年多器官疾病杂志, 2015, 14(9):683-686.
[25] 乔俊英, 李远哲, 李利平,等. 重度肺炎患儿血清 Clara 细胞分泌蛋白 16 和肺表面活性蛋白 D 水平及临床意义[J]. 临床儿科杂志, 2018, 36(2):81-86.

快速检索引用检索图表检索高级检索